EGFR and neoplasm: Cetuximab (IgG1 chimeric) and panitumumab (IgG2 fully humanized) are clinically approved anti-EGFR mAbs that bind to the extracellular domain of EGFR thereby blocking EGFR dimerization, resulting in apoptosis and preventing tumor growth [3].